文献速递浆细胞疾病

Forimtamig(GPRC5DxCD3双特异性抗体)治疗复发/难治多发性骨髓瘤的1期研究

Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma.
PubMed 文献 · Blood Adv · 2026-09-30

这项1期研究评估了皮下注射forimtamig(一种新型2:1构型的GPRC5DxCD3双特异性抗体)在复发/难治多发性骨髓瘤(RRMM)患者中的安全性和疗效。共纳入171例患者,最常见不良事件为细胞因子释放综合征(75.4%)。在优化目标剂量(0.75 mg/1.5 mg)下, condensed step-up方案的ORR为71.7%,每周方案为47.1%。

要点

  • Forimtamig在RRMM中显示出强效且持久的抗肿瘤活性。
  • Condensed step-up方案可提高客观缓解率(ORR 71.7% vs 47.1%)。
  • 靶向、脱肿瘤毒性常见,提示GPRC5D靶点治疗窗较窄。

核心结论

  • 皮下注射forimtamig在复发/难治多发性骨髓瘤中表现出强效且持久的活性,condensed step-up方案可增强疗效。

研究设计与样本

  • 1期研究(NCT04557150),纳入171例复发/难治多发性骨髓瘤患者,评估皮下注射forimtamig的安全性和疗效。

主要发现

  • 最常见不良事件为细胞因子释放综合征(75.4%)。
  • 剂量限制性毒性发生于20例患者(11.7%),未确定最大耐受剂量。
  • 总体客观缓解率(ORR)为59.6%;在优化目标剂量(0.75 mg/1.5 mg)下,condensed方案ORR为71.7%(n=46),每周方案为47.1%(n=34)。
  • 早期可溶性B细胞成熟抗原下降和微小残留病阴性与无进展生存期改善相关。

关键数值与推荐

  • 起始剂量(C1D1)为0.05 mg。
  • 剂量递增因累积毒性在目标剂量7.2 mg时终止。
  • 优化目标剂量为0.75 mg/1.5 mg。

临床怎么用

  • Forimtamig可能成为RRMM的治疗选择,condensed step-up方案或可提高缓解率。
  • 需密切监测细胞因子释放综合征等靶向、脱肿瘤毒性。

局限性

  • 未确定最大耐受剂量。
  • 靶向、脱肿瘤毒性常见,治疗窗较窄。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We report the results from a Phase 1 study (NCT04557150) evaluating subcutaneous (SC) forimtamig, a novel GPRC5DxCD3 bispecific antibody with a 2:1 configuration, in relapsed/refractory multiple myeloma (RRMM). After dose-escalation, backfilling at optimized target doses in combination with weekly (step-up: Cycle [C] 1 Day [D] 1 and C1D8; target: C1D15) and condensed (step-up: C1D1 and C1D4; target: C1D8) step-up dosing was pursued for benefit-risk assessment. Primary objectives were evaluating safety/tolerability and determining the maximum tolerated dose (MTD) and recommended Phase 2 dose/schedule. Secondary objectives included pharmacokinetics, immunogenicity and anti-tumor activity. In total, 171 patients were enrolled (median age: 64.0 years; high-risk cytogenetics: 32.2%; triple-class refractory: 60.2%). The starting C1D1 dose was 0.05 mg. Dose-limiting toxicities occurred in 20 patients (11.7%). MTD was not identified. Dose-escalation concluded at 7.2 mg target dose due to accumulating toxicity. The most common adverse event (AE) was cytokine release syndrome (75.4%). Grade 5 AEs occurred in 11 patients (6.4%); two events were considered treatment-related. Across all cohorts, the overall response rate (ORR) was 59.6%. At the optimized target doses (0.75 mg/1.5 mg), ORR was 71.7% with the condensed schedule (n = 46) and 47.1% with the weekly schedule (n = 34). Early soluble B-cell maturation antigen reduction and minimal residual disease negativity were associated with improved progression-free survival. SC forimtamig demonstrated potent and durable activity in RRMM, which could be enhanced with a condensed step-up schedule. On-target, off-tumor toxicities were common, highlighting the narrow therapeutic window for GPRC5D as a target for T-cell-engaging bispecific antibodies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hasselbalch AC, Harrison SJ, Manier S, et al. Forimtamig, a GPRC5DxCD3 bispecific antibody with a novel 2:1 format, in relapsed/refractory multiple myeloma. Blood Adv. 2026. PMID: 42815880. doi:10.1182/bloodadvances.2026020498

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。